Kemeny N, Lokich J J, Anderson N, Ahlgren J D
Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
Cancer. 1993 Jan 1;71(1):9-18. doi: 10.1002/1097-0142(19930101)71:1<9::aid-cncr2820710104>3.0.co;2-y.
The treatment of advanced colorectal cancer has improved in recent years. Prospective randomized trials comparing innovative therapies with the "standard" bolus dose of 5-fluorouracil (5-FU) found increased response rates after biochemical modification of the drug, infusion administration of 5-FU, and direct intrahepatic arterial infusion. Although the impact on survival of these techniques has been minimal, it is possible that these innovative approaches provide an incremental survival advantage for certain subgroups of patients that may be the foundation for additional therapeutic improvements in the future.
近年来,晚期结直肠癌的治疗已有改善。将创新疗法与“标准”推注剂量的5-氟尿嘧啶(5-FU)进行比较的前瞻性随机试验发现,药物经生化修饰、5-FU静脉滴注给药以及直接肝内动脉灌注后,缓解率有所提高。尽管这些技术对生存率的影响微乎其微,但这些创新方法有可能为某些亚组患者提供额外的生存优势,这可能成为未来进一步治疗改善的基础。